Oral Budesonide Suspension (OBS) in Eosinophilic Esophagitis

To demonstrate in a placebo-controlled trial that: · OBS induces a histologic response (eosinophilic count ≤6/high-powered field [HPF]) in adolescent and adult subjects with eosinophilic esophagitis (EoE) over a 12-week course of therapy. · OBS reduces dysphagia, as measured by the Dysphagia Symptom Questionnaire (DSQ), by at least 30% from baseline in adolescent and adult subjects with EoE over a 12-week course of therapy.

July 11, 2016